Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib

Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib

imedex

1 year
601 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Earn CME: https://naccme.com/program/7314

In this presentation from the 'Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. Jennifer R. Brown provides an update on PI3K inhibitors for CLL.

© 2018 Imedex, an HMP Company
Up Next Autoplay